Birbari A E, Dauk M, Mukaddam-Daher S
Angiology. 1987 May;38(5):363-7. doi: 10.1177/000331978703800503.
Fifteen elderly hypertensives aged fifty-nine to seventy-four years received captopril either as a monotherapy (group I, n=7) or as an addition to other antihypertensive drugs (group II, n=8) for twelve to fourteen months. Both the mean supine and erect blood pressure fell from 173.3 +/- 3.4/93.3 +/- 6.6 to 143.3 +/- 3.4/78.3 +/- 1.7 and from 166.7 +/- 8.6/98.3 +/- 4.4 to 146.7 +/- 12.0/85.0 +/- 2.9 mm Hg, respectively, in group I, and from 165.6 +/- 10.5/104.9 +/- 4.4 to 128.8 +/- 4.7/84.1 +/- 1.7 and from 154.0 +/- 10.1/107.8 +/- 3.3 to 126.3 +/- 6.0/88.8 +/- 1.2 mm Hg, respectively, in group II. There was a slight but insignificant reduction in pulse rate and body weight. Side effects were minimal. All patients experienced a sense of well-being. There was no impairment of renal function in most patients and no reduction in serum K. This study suggests that, in elderly hypertensives, captopril reduces blood pressure safely and effectively without impairing perfusion to the brain, heart, and kidneys and without causing edema or hypokalemia.
15名年龄在59至74岁之间的老年高血压患者接受了卡托普利治疗，治疗时间为12至14个月，其中7名患者采用单一疗法（第一组），8名患者在其他抗高血压药物基础上加用卡托普利（第二组）。第一组患者仰卧位和直立位平均血压分别从173.3±3.4/93.3±6.6降至143.3±3.4/78.3±1.7，以及从166.7±8.6/98.3±4.4降至146.7±12.0/85.0±2.9 mmHg；第二组患者仰卧位和直立位平均血压分别从165.6±10.5/104.9±4.4降至128.8±4.7/84.1±1.7，以及从154.0±10.1/107.8±3.3降至126.3±6.0/88.8±1.2 mmHg。脉搏率和体重有轻微但不显著的下降。副作用极小。所有患者都感觉良好。大多数患者肾功能无损害，血清钾也未降低。本研究表明，在老年高血压患者中，卡托普利能安全有效地降低血压，且不损害脑、心脏和肾脏的灌注，不引起水肿或低钾血症。
